诺和诺德表示,与礼来公司的Mounjaro相比,Ozempic的心血管事件风险较低

路透中文
Sep 29
<a href="https://laohu8.com/S/NVO">诺和诺德</a>表示,与<a href="https://laohu8.com/S/LLY">礼来</a>公司的Mounjaro相比,Ozempic的心血管事件风险较低

路透哥本哈根9月29日 - 诺和诺德 NOVOb.CO 周二表示,一项真实世界研究发现,与改用礼来公司Mounjaro的2型糖尿病成人患者相比,将糖尿病药物Ozempic的剂量从1毫克增加至2毫克的患者,发生重大心血管事件的风险较低。

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10